Abstract
What is already known about this topic? Two 2-dose mRNA COVID-19 vaccines (from Pfizer-BioNTech and Moderna) and a 1-dose viral vector vaccine (from Janssen [Johnson & Johnson]) are currently used in the United States. What is added by this report? Among U.S. adults without immunocompromising conditions, vaccine effectiveness against COVID-19 hospitalization during March 11-August 15, 2021, was higher for the Moderna vaccine (93%) than the Pfizer-BioNTech vaccine (88%) and the Janssen vaccine (71%). What are the implications for public health practice? Although these real-world data suggest some variation in levels of protection by vaccine, all FDA-approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1337-1343 |
| Number of pages | 7 |
| Journal | Morbidity and Mortality Weekly Report |
| Volume | 70 |
| Issue number | 38 |
| DOIs | |
| State | Published - Sep 2021 |
ASJC Scopus subject areas
- Epidemiology
- Health(social science)
- Health, Toxicology and Mutagenesis
- Health Information Management
Fingerprint
Dive into the research topics of 'Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations among Adults without Immunocompromising Conditions - United States, March-August 2021'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations among Adults without Immunocompromising Conditions - United States, March-August 2021. / Self, Wesley H.; Tenforde, Mark W.; Rhoads, Jillian P.; Gaglani, Manjusha; Ginde, Adit A.; Douin, David J.; Olson, Samantha M.; Talbot, H. Keipp; Casey, Jonathan D.; Mohr, Nicholas M.; Zepeski, Anne; McNeal, Tresa; Ghamande, Shekhar; Gibbs, Kevin W.; Files, D. Clark; Hager, David N.; Shehu, Arber; Prekker, Matthew E.; Erickson, Heidi L.; Gong, Michelle N.; Mohamed, Amira; Henning, Daniel J.; Steingrub, Jay S.; Peltan, Ithan D.; Brown, Samuel M.; Martin, Emily T.; Monto, Arnold S.; Khan, Akram; Hough, Catherine L.; Busse, Laurence W.; Lohuis, Caitlin C.Ten; Duggal, Abhijit; Wilson, Jennifer G.; Gordon, Alexandra June; Qadir, Nida; Chang, Steven Y.; Mallow, Christopher; Rivas, Carolina; Babcock, Hilary M.; Kwon, Jennie H.; Exline, Matthew C.; Halasa, Natasha; Chappell, James D.; Lauring, Adam S.; Grijalva, Carlos G.; Rice, Todd W.; Jones, Ian D.; Stubblefield, William B.; Baughman, Adrienne; Womack, Kelsey N.; Lindsell, Christopher J.; Hart, Kimberly W.; Zhu, Yuwei; Mills, Lisa; Lester, Sandra N.; Stump, Megan M.; Naioti, Eric A.; Kobayashi, Miwako; Verani, Jennifer R.; Thornburg, Natalie J.; Patel, Manish M.
In: Morbidity and Mortality Weekly Report, Vol. 70, No. 38, 09.2021, p. 1337-1343.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations among Adults without Immunocompromising Conditions - United States, March-August 2021
AU - Self, Wesley H.
AU - Tenforde, Mark W.
AU - Rhoads, Jillian P.
AU - Gaglani, Manjusha
AU - Ginde, Adit A.
AU - Douin, David J.
AU - Olson, Samantha M.
AU - Talbot, H. Keipp
AU - Casey, Jonathan D.
AU - Mohr, Nicholas M.
AU - Zepeski, Anne
AU - McNeal, Tresa
AU - Ghamande, Shekhar
AU - Gibbs, Kevin W.
AU - Files, D. Clark
AU - Hager, David N.
AU - Shehu, Arber
AU - Prekker, Matthew E.
AU - Erickson, Heidi L.
AU - Gong, Michelle N.
AU - Mohamed, Amira
AU - Henning, Daniel J.
AU - Steingrub, Jay S.
AU - Peltan, Ithan D.
AU - Brown, Samuel M.
AU - Martin, Emily T.
AU - Monto, Arnold S.
AU - Khan, Akram
AU - Hough, Catherine L.
AU - Busse, Laurence W.
AU - Lohuis, Caitlin C.Ten
AU - Duggal, Abhijit
AU - Wilson, Jennifer G.
AU - Gordon, Alexandra June
AU - Qadir, Nida
AU - Chang, Steven Y.
AU - Mallow, Christopher
AU - Rivas, Carolina
AU - Babcock, Hilary M.
AU - Kwon, Jennie H.
AU - Exline, Matthew C.
AU - Halasa, Natasha
AU - Chappell, James D.
AU - Lauring, Adam S.
AU - Grijalva, Carlos G.
AU - Rice, Todd W.
AU - Jones, Ian D.
AU - Stubblefield, William B.
AU - Baughman, Adrienne
AU - Womack, Kelsey N.
AU - Lindsell, Christopher J.
AU - Hart, Kimberly W.
AU - Zhu, Yuwei
AU - Mills, Lisa
AU - Lester, Sandra N.
AU - Stump, Megan M.
AU - Naioti, Eric A.
AU - Kobayashi, Miwako
AU - Verani, Jennifer R.
AU - Thornburg, Natalie J.
AU - Patel, Manish M.
N1 - Funding Information: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Wesley H. Self reports grants and consultant fees from Merck and consultant fees from Aerpio Pharmaceuticals. Adit A. Ginde reports grant support from AbbVie and Faron Pharmaceuticals. Jonathan D. Casey reports a grant (N23HL153584) from the National Institutes of Health (NIH). D. Clark Files reports consultant fees from Cytovale and membership on a Medpace Data Safety Monitoring Board (DSMB). David N. Hager reports salary support from Incyte Corporation, EMPACT Precision Medicine, and the Marcus Foundation. Michelle N. Gong reports grant support from NIH and the Agency for Healthcare Research and Quality (AHRQ) and fees for participating on a DSMB for Regeneron and for participating on a scientific advisory panel for Philips Healthcare. Daniel J. Henning reports consulting fees from Cytovale and Opticyte. Ithan D. Peltan reports grants from NIH and Janssen Pharmaceuticals, institutional fees from Asahi Kasei Pharma and from Regeneron. Samuel M. Brown reports fees from Hamilton for chairing a DSMB, and institutional fees from Faron, Sedana, and Janssen; grants from Sedana, Janssen, NIH, and the Department of Defense (DoD); book royalties from Oxford University and Brigham Young University; and personal fees from New York University for service on a DSMB. Emily T. Martin reports personal fees from Pfizer for unrelated work and a grant from Merck for unrelated work. Akram Khan reports grants from United Therapeutics, Johnson & Johnson, 4D Medical, Lung LLC, and Reata Pharmaceuticals. Arnold S. Monto reports consulting fees from Sanofi-Pasteur and Seqirus. Steven Y. Chang was a speaker for La Jolla Pharmaceuticals and a Consultant for PureTech Health. Jennie H. Kwon reports grant support from NIH. Matthew C. Exline reports talks on nutrition in COVID pneumonia at APEN conference sponsored by Abbott Labs. Natasha Halasa reports grants from Sanofi and Quidel. James D. Chappell reports a grant from the National Center for Advancing Translational Sciences, NIH. Adam S. Lauring reports consultant fees from Sanofi and fees from Roche for membership on a trial steering committee. Carlos G. Grijalva reports consultant fees from Pfizer, Merck, and Sanofi-Pasteur and grants from Campbell Alliance/Syneos Health, NIH, the Food and Drug Administration, AHRQ, and Sanofi. Todd W. Rice reports personal fees from Cumberland Pharmaceuticals, Inc., as the Director of Medical Affairs, consultant fees from Avisa Pharma, LLC; and DSMB membership fees from Sanofi. Christopher J. Lindsell reports grants from NIH, DoD, and the Marcus Foundation; organizational contract fees from bioMerieux, Endpoint LLC, and Entegrion, Inc.; and a patent issued to Cincinnati Children’s Hospital Medical Center for risk stratification in sepsis and septic shock. No other potential conflicts of interest were disclosed. Publisher Copyright: © 2021 Department of Health and Human Services. All rights reserved.
PY - 2021/9
Y1 - 2021/9
N2 - What is already known about this topic? Two 2-dose mRNA COVID-19 vaccines (from Pfizer-BioNTech and Moderna) and a 1-dose viral vector vaccine (from Janssen [Johnson & Johnson]) are currently used in the United States. What is added by this report? Among U.S. adults without immunocompromising conditions, vaccine effectiveness against COVID-19 hospitalization during March 11-August 15, 2021, was higher for the Moderna vaccine (93%) than the Pfizer-BioNTech vaccine (88%) and the Janssen vaccine (71%). What are the implications for public health practice? Although these real-world data suggest some variation in levels of protection by vaccine, all FDA-approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization.
AB - What is already known about this topic? Two 2-dose mRNA COVID-19 vaccines (from Pfizer-BioNTech and Moderna) and a 1-dose viral vector vaccine (from Janssen [Johnson & Johnson]) are currently used in the United States. What is added by this report? Among U.S. adults without immunocompromising conditions, vaccine effectiveness against COVID-19 hospitalization during March 11-August 15, 2021, was higher for the Moderna vaccine (93%) than the Pfizer-BioNTech vaccine (88%) and the Janssen vaccine (71%). What are the implications for public health practice? Although these real-world data suggest some variation in levels of protection by vaccine, all FDA-approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization.
UR - http://www.scopus.com/inward/record.url?scp=85116863680&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116863680&partnerID=8YFLogxK
U2 - 10.15585/MMWR.MM7038E1
DO - 10.15585/MMWR.MM7038E1
M3 - Article
C2 - 34555004
AN - SCOPUS:85116863680
VL - 70
SP - 1337
EP - 1343
JO - Morbidity and Mortality Weekly Report
JF - Morbidity and Mortality Weekly Report
SN - 0149-2195
IS - 38
ER -